Active substance
Results for the substance osimertinib
2 results
About this active substance
Osimertinib is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. It works by blocking EGFR signaling, inhibiting tumor cell growth.
The medication is administered orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as diarrhea, skin rashes, or elevated liver enzymes. It is important to inform the doctor of any unusual symptoms.
Common side effects include diarrhea, skin rashes, and elevated liver enzymes. In rare cases, severe reactions such as pulmonary toxicity or cardiotoxicity may occur. Patients should be informed of these risks before use.
The medication is administered orally, as directed by a doctor, usually once daily. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as diarrhea, skin rashes, or elevated liver enzymes. It is important to inform the doctor of any unusual symptoms.
Common side effects include diarrhea, skin rashes, and elevated liver enzymes. In rare cases, severe reactions such as pulmonary toxicity or cardiotoxicity may occur. Patients should be informed of these risks before use.